- Home
- RLYB
RLYB
Rallybio Corporation
as 12-26-2024 4:00pm EST
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 45.2M | IPO Year: | 2021 |
| Target Price: | $8.10 | AVG Volume (30 days): | 125.7K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.84 - $3.46 | Next Earning Date: | 11-07-2024 |
| Revenue: | $598,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -62.94% |
Latest Rallybio Corporation News
RLYB Breaking Stock News: Dive into RLYB Ticker-Specific Updates for Smart Investing
Simply Wall St.
14 days ago
US Penny Stocks To Consider In December 2024
Business Wire
16 days ago
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
TipRanks
20 days ago
Rallybio price target lowered to $7 from $8 at JMP Securities
Business Wire
24 days ago
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
Business Wire
a month ago
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
Business Wire
a month ago
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference
Business Wire
a month ago
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor
Clinical Trials Arena
a month ago
Rallybio commences Phase II trial of RLYB212 for FNAIT in pregnant women
Compare RLYB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLYB Rallybio Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.